ATE293689T1 - Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung - Google Patents

Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung

Info

Publication number
ATE293689T1
ATE293689T1 AT96900656T AT96900656T ATE293689T1 AT E293689 T1 ATE293689 T1 AT E293689T1 AT 96900656 T AT96900656 T AT 96900656T AT 96900656 T AT96900656 T AT 96900656T AT E293689 T1 ATE293689 T1 AT E293689T1
Authority
AT
Austria
Prior art keywords
rantes
mip
mcp
chemokine receptor
alpha
Prior art date
Application number
AT96900656T
Other languages
English (en)
Inventor
Timothy Nigel Carl Wells
Christine Anna Power
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293689(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE293689T1 publication Critical patent/ATE293689T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
AT96900656T 1995-01-27 1996-01-24 Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung ATE293689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501683.8A GB9501683D0 (en) 1995-01-27 1995-01-27 Substances and their uses
PCT/GB1996/000143 WO1996023068A1 (en) 1995-01-27 1996-01-24 A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses

Publications (1)

Publication Number Publication Date
ATE293689T1 true ATE293689T1 (de) 2005-05-15

Family

ID=10768728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96900656T ATE293689T1 (de) 1995-01-27 1996-01-24 Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung

Country Status (9)

Country Link
US (4) US6150132A (de)
EP (1) EP0805859B2 (de)
JP (2) JP3771585B2 (de)
AT (1) ATE293689T1 (de)
AU (1) AU4455896A (de)
DE (1) DE69634627T3 (de)
ES (1) ES2240989T5 (de)
GB (1) GB9501683D0 (de)
WO (1) WO1996023068A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501683D0 (en) * 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
EP2034023A1 (de) * 1996-03-01 2009-03-11 Euroscreen S.A. CC-Chemokinzeptor C-C CKR-5, dessen Derivate und Verwendungen
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US5939320A (en) * 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
US5955303A (en) * 1997-03-06 1999-09-21 Incyte Pharmaceuticals, Inc. Human chemokine receptor-like protein
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
US6121023A (en) * 1998-01-22 2000-09-19 Akzo Nobel N.V. Isothermal transcription based assay for the detection and quantification of the chemokine rantes
US6287805B1 (en) 1998-03-20 2001-09-11 Millennium Pharmaceuticals, Inc. Nucleic acid molecules of the protein-coupled heptahelical receptor superfamily and uses therefor
CA2341361A1 (en) * 1998-08-31 2000-03-09 Oregon Health Sciences University Prevention of cell migration initiation with cmv us28 receptor antagonists
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
ES2156526B1 (es) * 1999-01-20 2002-02-01 Smithkline Beecham Sa Metabolitos de streptomyces cacaoi como inhibidores de la proteina quimioatrayente de monocitos 1.
ES2420835T3 (es) * 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
JP3707303B2 (ja) 1999-06-30 2005-10-19 株式会社日立製作所 ヒスタミン計測方法およびヒスタミン計測装置
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7335647B2 (en) 2000-10-11 2008-02-26 Kensuke Egashira Drugs for liver diseases
KR100360410B1 (ko) * 2000-11-14 2002-11-13 삼성전자 주식회사 자기 정렬된 컨택 구조를 갖는 디램 소자와 듀얼 게이트구조의 로직 소자가 복합된 ｍｄｌ 반도체 소자의 제조 방법
US20020111290A1 (en) * 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
WO2002062296A2 (en) * 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20020165161A1 (en) * 2001-05-04 2002-11-07 Surromed, Inc. Chemokine-binding proteins for treating congestive heart failure
ES2330731T3 (es) * 2001-08-30 2009-12-15 Chemocentryx, Inc. Compuestos biciclicos como inhibidores de la union de quimioquina a us28.
US7504104B2 (en) 2001-08-31 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Human CDR-grafted antibody and antibody fragment thereof
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
WO2004020584A2 (en) 2002-08-27 2004-03-11 Bristol-Myers Squibb Company Antagonists of chemokine receptors
JP2008507255A (ja) 2004-03-12 2008-03-13 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5179078A (en) * 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
AU5293293A (en) * 1992-09-28 1994-04-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of allergic disease
EP0669979B1 (de) * 1992-11-10 2005-10-12 Genentech, Inc. C-c ckr-1, ein c-c chemokin rezeptor
US5474983A (en) * 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
GB2294267B (en) 1993-06-03 1996-11-20 Therapeutic Antibodies Inc Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
JP3532570B2 (ja) * 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses

Also Published As

Publication number Publication date
US6150132A (en) 2000-11-21
DE69634627T3 (de) 2008-12-11
ES2240989T3 (es) 2005-10-16
US7655425B2 (en) 2010-02-02
US20020187930A1 (en) 2002-12-12
JP2003038191A (ja) 2003-02-12
GB9501683D0 (en) 1995-03-15
DE69634627D1 (de) 2005-05-25
ES2240989T5 (es) 2008-12-16
JP3771585B2 (ja) 2006-04-26
DE69634627T2 (de) 2006-03-02
AU4455896A (en) 1996-08-14
US20020160015A1 (en) 2002-10-31
EP0805859B2 (de) 2008-06-25
US6919432B2 (en) 2005-07-19
US20050014695A1 (en) 2005-01-20
WO1996023068A1 (en) 1996-08-01
EP0805859B1 (de) 2005-04-20
EP0805859A1 (de) 1997-11-12
JPH10513046A (ja) 1998-12-15
US7183063B2 (en) 2007-02-27

Similar Documents

Publication Publication Date Title
ATE293689T1 (de) Ein chemokin rezeptor für mcp-i, mip-i alpha und/oder rantes.seine verwendung
Almeida et al. NAP-2 secreted by human NK cells can stimulate mesenchymal stem/stromal cell recruitment
Qin et al. CCL2 and CXCL1 trigger calcitonin gene‐related peptide release by exciting primary nociceptive neurons
BR0316880A (pt) Anticorpos contra pd-1 e usos dos mesmos
ES2128544T3 (es) Pirrolopirimidinas como antagonistas del crf.
DE69813237T2 (de) Zusammensetzungen zur behandlung von durch ccr5 mediatierten erkrankungen
BG99605A (en) Antagonists of the growth factor or endothelial cells of the circulatory system
Gouwy et al. CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual‐tropic (R5/X4) HIV‐1 infection
DE69508093D1 (de) Substituierte piperidine für die behandlung von allergischen krankheiten
Sebastiani et al. CCL22‐induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first β‐strand of chemokine
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE360441T1 (de) Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
Mullazehi et al. Surface‐bound anti–type II collagen–containing immune complexes induce production of tumor necrosis factor α, interleukin‐1β, and interleukin‐8 from peripheral blood monocytes via fcγ receptor IIA: A potential pathophysiologic mechanism for humoral anti–type II collagen immunity in arthritis
Gómez et al. Thorns as induced mechanical defense in a long‐lived shrub (Hormathophylla spinosa, Cruciferae)
MA27606A1 (fr) Association destinée au traitement de l'ADHD
DE602004012403D1 (de) Zusammensetzungen zur beeinflussung des gewichtsverlusts
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
Banke The dilated TRPA1 channel pore state is blocked by amiloride and analogues
DE60323091D1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
Luce et al. Decrease in CD38+ TH2A cell frequencies following immunotherapy with house dust mite tablet correlates with humoral responses
ATE292677T1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
DE50009113D1 (de) Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
ATE343398T1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
EP1255112A3 (de) Behandlung von T-Zellen vermittelter Krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties